


**APPROACHES TO THE FULLY FUNCTIONALIZED DEF RING  
SYSTEM OF RISTOCETIN A VIA HIGHLY SELECTIVE  
RUTHENIUM-PROMOTED S<sub>N</sub>Ar REACTION**



**Anthony J. Pearson\* and Jung-Nyoung Heo**

*Department of Chemistry, Case Western Reserve University, Cleveland, OH 44106*

*ajp4@po.cwru.edu*

**SUPPLEMENTARY MATERIAL**

**Experimental**

**(S)-N-(Benzyloxycarbonyl)-1-(3-benzyloxy-5-methoxy-4-methyl-phenyl)-2-hydroxyethylamine (11).** To a solution of benzyl carbamate (380 mg, 2.51 mmol, 3.1 equiv) in 1-propanol (5 mL) was added an aqueous solution of NaOH (99 mg, 2.47 mmol, 3.05 equiv) in H<sub>2</sub>O (6 mL), followed by *t*-butyl hypochlorite (268 mg, 2.47 mmol, 3.05 equiv). After 5 min a solution of (DHQ)<sub>2</sub>PHAL (32 mg, 0.04 mmol, 5 mol %) in 1-propanol (4 mL) was added to the above solution. Styrene **10** (206 mg, 0.81 mmol) dissolved in ethyl ether (3 mL) was then added, followed by K<sub>2</sub>OsO<sub>2</sub>(OH)<sub>4</sub> (12 mg, 0.032 mmol, 4 mol %). The resulting emulsion was stirred at rt for 1h until the mixture became a clear light yellow solution. The reaction was cooled to 0 °C and quenched with saturated Na<sub>2</sub>SO<sub>3</sub> solution (10 mL) and further stirred for 15 min. The mixture was extracted with EtOAc (3 x 15 mL). The combined organic layers were washed with water (15 mL), brine (15 mL), dried (MgSO<sub>4</sub>), and concentrated to provide the crude mixture of regioisomers (1°/2° alcohol = 4/1). Flash chromatography (2:3 EtOAc/hexanes) gave 227 mg (66%) of the desired 1° alcohol **11** as a colorless solid and 57 mg (17%) of the 2° alcohol. For 1° alcohol: mp 115-118 °C; R<sub>f</sub> = 0.20 (2:3 EtOAc/hexanes); [α]<sub>D</sub><sup>25</sup> +25.5 (c 1.0, CHCl<sub>3</sub>); <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) δ 7.44-7.31 (m, 10H), 6.52 (s, 1H), 6.47 (s, 1H), 5.53 (bs, 1H), 5.11 (s, 2H), 5.04 (s, 2H), 4.77 (s, 1H), 3.83 (d, 2H, *J* = 3.9 Hz), 3.80 (s, 3H), 2.13 (s, 3H), 2.02 (bs, 1H); <sup>13</sup>C NMR (CDCl<sub>3</sub>, 50 MHz) δ 158.8, 157.7, 156.6, 137.8, 137.4, 136.3, 128.6, 128.3, 127.9, 127.3, 114.8, 103.4, 102.2, 70.4, 67.2, 66.6, 57.7, 55.8, 8.5; IR (KBr) 3335, 1693, 1592, 1539, 1267, 1138 cm<sup>-1</sup>; HRMS (EI) *m/z* 421.1879 for M<sup>+</sup> (421.1889 calcd for C<sub>25</sub>H<sub>27</sub>NO<sub>5</sub>).

**(S)-N-(Benzyloxycarbonyl)-(3-benzyloxy-5-methoxy-4-methylphenyl)-glycine (12).** A solution of alcohol **11** (248 mg, 0.59 mmol) in acetone (5.0 mL) at 0 °C was added to an aqueous 5% NaHCO<sub>3</sub> (1.5 mL). This colloidal mixture was treated with KBr (10 mg, 0.08 mmol, 0.14 equiv) and TEMPO (98 mg, 0.62 mmol, 1.05 equiv) sequentially. Sodium hypochlorite (2.0 mL, 1.2 mmol, 2.0 equiv, 4-6% chlorine) was added slowly for 10min. The mixture was stirred at 0 °C for 2.5h, and then concentrated *in vacuo*. The residue was treated with H<sub>2</sub>O (10 mL) and washed with diethyl ether (2 x 10 mL). The aqueous solution was acidified to pH = 6 with 10% aqueous citric acid solution and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with H<sub>2</sub>O (20 mL), brine (20 mL), dried (MgSO<sub>4</sub>), and concentrated to give 182 mg (71%) of phenylglycine **12** as a white solid: mp 148-150 °C; *R*<sub>f</sub> = 0.27 (10% MeOH/CHCl<sub>3</sub>); [ $\alpha$ ]<sub>D</sub><sup>25</sup> +94 (*c* 1.0, EtOH); <sup>1</sup>H NMR (DMSO-*d*<sub>6</sub>, 300 MHz)  $\delta$  12.88 (bs, 1H), 8.06 (d, 1H, *J* = 8.4 Hz), 7.47-7.31 (m, 10H), 6.84 (s, 1H), 6.72 (s, 1H), 5.09 (d, 1H, *J* = 8.4 Hz), 5.06 (s, 4H), 3.76 (s, 3H), 2.00 (s, 3H); <sup>13</sup>C NMR (Acetone-*d*<sub>6</sub>, 50 MHz)  $\delta$  172.6, 159.5, 158.5, 156.7, 138.6, 138.2, 136.8, 129.4, 129.3, 128.9, 128.8, 128.7, 128.5, 115.0, 105.5, 104.2, 71.0, 67.1, 59.4, 56.2, 8.8; IR (KBr) 3390, 1740, 1679, 1602, 1542, 1432, 1246, 1142, 1059 cm<sup>-1</sup>; HRMS (EI) *m/z* 435.1683 for M<sup>+</sup> (435.1682 calcd for C<sub>25</sub>H<sub>25</sub>NO<sub>6</sub>).

**N-Methyl (2R)-2-[(S)-1-(((benzyloxy)carbonyl)amino)-1-(3-benzyloxy-5-methyl-4-methylphenyl)methylcarboxamido]-2-(3,5-dihydroxy-4-methoxyphenyl)ethanamide (14).** To a solution of the *N*-methyl azidoacetamide **13** (52 mg, 0.12 mmol) in THF-MeOH (2 mL/2 mL) was added 10% Pd/C (14 mg) and 6N HCl (60  $\mu$ L, 0.36 mmol, 3.0 equiv). The suspension was stirred under 1 atm H<sub>2</sub> (balloon) for 12h. The mixture was filtered through Celite and evaporated. The residue was chased with anhydrous diethyl ether (20 mL) and dried under vacuum to provide the crude amine hydrochloride as a light green film.

(*S*)-aryl glycine **12** (52 mg, 0.12 mmol, 1.0 equiv), HOAt (25 mg, 0.18 mmol, 1.5 equiv), and EDCI (35 mg, 0.18 mmol, 1.5 equiv) were sequentially added to a solution of the above amine hydrochloride in DMF-CH<sub>2</sub>Cl<sub>2</sub> (1.5 mL/1.5 mL), followed by TMP (32  $\mu$ L, 0.24 mmol, 2.0 equiv) at 0 °C. The mixture was stirred at 0 °C for 3h, and then at rt for 17h. The mixture was diluted with EtOAc (30 mL) and washed with 1M NaHSO<sub>4</sub> (2 x 10 mL), saturated aqueous NaHCO<sub>3</sub> (2 x 10 mL), H<sub>2</sub>O (10 mL), and brine (20 mL). The organic phase was dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated. The residue was purified by flash chromatography (80% → 90% EtOAc/hexanes, gradient elution) to afford 70 mg (91%) of


the dipeptide **14** as a white solid:  $R_f = 0.56$  (1:9 MeOH/ $\text{CHCl}_3$ );  $[\alpha]_D^{25} -18.5$  ( $c$  0.2, MeOH);  $^1\text{H}$  NMR ( $\text{CD}_3\text{CN}$ , 300 MHz)  $\delta$  7.42-7.31 (m, 11H), 6.81 (s, 2H), 6.68 (s, 1H), 6.61 (bs, 1H), 6.59 (s, 1H), 6.40 (bs, 1H), 6.24 (s, 2H), 5.21 (d, 1H,  $J = 7.5$  Hz), 5.07-5.05 (m, 3H), 4.97 (s, 2H), 3.71 (s, 3H), 3.68 (s, 3H), 2.63 (d, 3H,  $J = 4.8$  Hz), 2.02 (s, 3H);  $^{13}\text{C}$  NMR (Acetone- $d_6$  +  $\text{CD}_3\text{OD}$ , 50 MHz)  $\delta$  170.8, 170.2, 158.1, 157.2, 156.2, 137.3, 136.7, 135.9, 135.0, 133.0, 128.0, 127.5, 127.4, 127.3, 127.2, 113.6, 106.4, 103.8, 102.6, 69.7, 66.1, 59.2, 58.6, 56.9, 54.7, 25.0, 7.2; FABHRMS (NBA/PEG246)  $m/z$  666.2447 for  $\text{M}^+ + \text{Na}$  (666.2427 calcd for  $\text{C}_{35}\text{H}_{37}\text{N}_3\text{O}_9\text{Na}$ ).

( $\eta^5$ -2,4-Cyclopentadien-1-yl) {*N*-methyl (2*R*)-2-[(*S*)-1-((1*R*, 2*R*)-1-((*tert*-butyloxycarbonyl)amino)-2-(*tert*-butyldimethylsilyloxy)-2-((1,2,3,4,5,6,-*h*)-4-chlorophenyl)ethylcarboxamido)-1-(3-benzyloxy-5-methoxy-4-methylphenyl)methylcarboxamido]-2-(3,5-dihydroxy-4-methoxyphenyl)ethanamido} ruthenium(II) hexafluorophosphate (**16**). To a solution of the dipeptide **14** (44 mg, 0.068 mmol) in MeOH/THF (1.5 mL/1.5 mL) was added 10% Pd/C (13 mg) and 6N HCl (34  $\mu\text{L}$ , 0.21 mmol, 3.0 equiv). The suspension was stirred under 1 atm  $\text{H}_2$  (balloon) for 20h. The mixture was filtered through Celite and evaporated. The residue was chased with anhydrous diethyl ether (20 mL) and dried under vacuum to provide the crude amine hydrochloride as a light yellow film. This amine hydrochloride was dissolved in DMF (1.5 mL), and the arylserine-ruthenium complex **15** (60 mg, 0.082 mmol, 1.2 equiv) and HATU (52 mg, 0.14 mmol, 2.0 equiv) was sequentially added at 0 °C. To this was added TMP (20  $\mu\text{L}$ , 0.15 mmol, 2.0 equiv) and stirred at 0 °C for 3h, and then at rt for 19h. The solution was diluted with  $\text{CH}_2\text{Cl}_2$  (30 mL) and washed with 1M  $\text{NaHSO}_4$  (2 x 10 mL), saturated aqueous  $\text{NaHCO}_3$  (2 x 10 mL),  $\text{H}_2\text{O}$  (10 mL), and brine (20 mL). The organic phase was dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated. The residue dissolved in  $\text{CH}_3\text{CN}$  (0.5 mL) was treated with diethyl ether/hexanes (30 mL/10 mL) and sonicated to precipitate the brown solid for 20 min. This was filtered, washed with diethyl ether (20 mL), and dried to provide 72 mg (92%) of the tripeptide ruthenium complex **16** as a brown powder:  $^1\text{H}$  NMR (Acetone- $d_6$  +  $\text{CD}_3\text{OD}$ , 300 MHz)  $\delta$  8.39 (d, 1H,  $J = 6.6$  Hz), 7.93 (d, 1H,  $J = 4.8$  Hz), 7.73 (d, 1H,  $J = 6.9$  Hz), 6.79 (d, 1H,  $J = 6.0$  Hz), 6.62 (d, 1H,  $J = 6.3$  Hz), 6.54-6.43 (m, 6H), 6.20 (d, 1H,  $J = 5.7$  Hz), 5.59 (s, 5H), 5.55 (d, 1H,  $J = 2.7$  Hz), 5.23 (d, 1H,  $J = 3.0$  Hz), 5.18 (d, 1H,  $J = 6.6$  Hz), 4.71 (d, 1H,  $J = 4.8$  Hz), 3.75 (s, 3H), 3.70 (s, 3H), 2.79 (d, 3H,  $J = 4.5$  Hz), 1.98 (s, 3H), 1.38 (s, 9H), 0.96 (s, 9H), 0.27 (s, 3H), 0.18 (s, 3H);  $^{13}\text{C}$  NMR ( $\text{CD}_3\text{CN}$ , 50 MHz)  $\delta$  172.5, 170.8, 169.4, 159.9, 156.9, 156.8, 151.7, 135.9, 135.4, 133.5, 113.5, 108.7, 107.6, 106.3, 105.6, 102.0, 87.6, 87.2, 85.3, 83.8, 83.7, 81.5, 72.1,


62.6, 60.8, 58.9, 58.2, 56.4, 28.4, 27.0, 26.0, 18.4, 8.5, -4.4, -4.8; FABHRMS (NBA/PEG246/NaI)  $m/z$  997.2760 for  $M^+ - PF_6^-$  (997.2760 calcd for  $C_{45}H_{60}ClN_4O_{11}SiRu$ ).


***N*-Methyl (8*R*,11*S*,14*R*,15*R*)-14-[*N*-[(*tert*-Butoxy)carbonyl] amino]-15-(*tert*-butyldimethylsilyloxy)-10,13-dioxo-5-hydroxy-4-methoxy-11-(3-benzyloxy-5-methoxy-4-methylphenyl)-2-oxa-9,12-diazatricyclo-[14.2.2.1<sup>3,7</sup>]heneicosa-3,4,7(21),16,18,19-hexaene-8-carboxamide (4).** To the tripeptide ruthenium complex **16** (40 mg, 0.035 mmol) in DMF (7.0 mL, 5 mM) was added  $Cs_2CO_3$  (57 mg, 0.175 mmol, 5.0 equiv) under argon atmosphere at room temperature. After 4h the mixture was diluted with  $CH_2Cl_2$  (20 mL) and washed with 1M  $NaHSO_4$  (2 x 10 mL),  $H_2O$  (2 x 10 mL), and brine (2 x 10 mL). The organic phase was dried ( $Na_2SO_4$ ), and concentrated.


The residue was dissolved in 20 mL of  $CH_3CN$ , degassed with Ar for 20 min, and photolyzed (Rayonet, 350 nm) for 24h. The solution was concentrated and purified by chromatography (50 → 80% EtOAc/hexanes, gradient elution) to obtain 17 mg (61%) of the cyclized product **4** as a white solid:  $R_f$  = 0.42 (80% EtOAc/hexanes);  $[\alpha]_D^{25}$  -19.1 (c 0.47, MeOH);  $^1H$  NMR (Acetone- $d_6$ , 300 MHz)  $\delta$  8.41 (s, 1H), 8.21 (s, 1H), 8.04 (d, 1H,  $J$  = 9.9 Hz), 7.71 (d, 1H,  $J$  = 8.1 Hz), 7.46 (d, 1H,  $J$  = 3.9 Hz), 7.35 (dd, 2H,  $J$  = 8.4, 2.4 Hz), 7.23 (dd, 2H,  $J$  = 8.7, 2.1 Hz), 6.95 (dd, 2H,  $J$  = 8.4, 2.4 Hz), 6.65 (d, 1H,  $J$  = 1.8 Hz), 6.54 (s, 2H), 5.75 (s, 1H), 5.67-5.63 (m, 2H), 5.34 (bs, 1H), 5.25 (d, 1H,  $J$  = 7.2 Hz), 4.76 (bs, 1H), 3.98 (s, 3H), 3.79 (s, 3H), 2.67 (s, 3H,  $J$  = 4.8 Hz), 2.02 (s, 3H), 1.47 (s, 9H), 0.99 (s, 9H), 0.22 (s, 3H), 0.13 (s, 3H);  $^{13}C$  NMR (Acetone- $d_6$ , 50 MHz)  $\delta$  170.3, 169.7, 169.6, 159.8, 157.8, 156.9, 156.8, 155.0, 151.7, 137.7, 137.1, 136.9, 134.7, 129.8, 127.6, 123.7, 123.0, 112.5, 108.9, 107.8, 106.5, 100.6, 80.4, 74.0, 63.0, 61.4, 58.4, 57.5, 56.1, 28.7, 26.5, 26.3, 19.0, 8.5, -4.7, -4.8; FABHRMS (NBA/PEG246)  $m/z$  795.3652 for  $MH^+$  (795.3636 calcd for  $C_{40}H_{55}N_4O_{11}Si$ ).




11 (CDCl<sub>3</sub>, 300 MHz)










12 (DMSO- $d_6$ , 300 MHz)













**16** ( $\text{CD}_3\text{OD} + \text{Acetone-}d_6$ , 300 MHz)

Chemical structure of **16** is shown, featuring a complex molecule with a ruthenium center coordinated by a cyclopentadienyl ligand and a chloride ligand, and a complex organic ligand containing multiple hydroxyl, methoxy, and amide groups.



<sup>1</sup>H NMR spectrum of compound 10b in CDCl<sub>3</sub>. The spectrum shows peaks from 0 to 10 ppm. Key peaks are labeled with chemical shifts and integrations: 0.1250 (3H), 0.2203 (3H), 1.4726 (2H), 1.3296 (2H), 2.0180 (2H), 2.1281 (2H), 2.6684 (2H), 2.6837 (2H), 3.7857 (2H), 3.9805 (2H), 5.5432 (1H), 6.5432 (1H), 7.2-7.8 (aromatic, 9.0-9.3 integration), 8.0-8.3 (aromatic, 11.0-11.3 integration), 9.0-9.3 (aromatic, 9.0-9.3 integration).

4 (Acetone- $d_6$ , 50 MHz)